Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1994 1
2001 1
2002 2
2004 2
2005 1
2006 4
2007 1
2008 1
2009 1
2010 2
2011 1
2013 4
2014 3
2015 3
2016 2
2019 1
2020 1
2022 2
2023 7
2024 11
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
The changing epidemiology of human monkeypox-A potential threat? A systematic review.
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. Bunge EM, et al. PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141. doi: 10.1371/journal.pntd.0010141. eCollection 2022 Feb. PLoS Negl Trop Dis. 2022. PMID: 35148313 Free PMC article.
Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. Since monkeypox in humans was initially diagnosed in 1970 in the Democratic Republic of the Congo (DRC), it has spread to other regions of Africa (primarily West and Cen …
Monkeypox, a zoonotic disease caused by an orthopoxvirus, results in a smallpox-like disease in humans. Since monkeypox in humans was …
Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
Pischel L, Martini BA, Yu N, Cacesse D, Tracy M, Kharbanda K, Ahmed N, Patel KM, Grimshaw AA, Malik AA, Goshua G, Omer SB. Pischel L, et al. Vaccine. 2024 Nov 14;42(25):126053. doi: 10.1016/j.vaccine.2024.06.021. Epub 2024 Jun 21. Vaccine. 2024. PMID: 38906763 Free article.
INTRODUCTION: Before the global mpox outbreak which began in 2022, the real-world vaccine effectiveness (VE) of mpox vaccines was unknown. We quantified the VE in the global population of 3rd generation or later mpox vaccines (MVA-BN, LC16m8, OrthopoxVac) com …
INTRODUCTION: Before the global mpox outbreak which began in 2022, the real-world vaccine effectiveness (VE) of mpox vaccines …
Predicting vaccine effectiveness for mpox.
Berry MT, Khan SR, Schlub TE, Notaras A, Kunasekaran M, Grulich AE, MacIntyre CR, Davenport MP, Khoury DS. Berry MT, et al. Nat Commun. 2024 May 8;15(1):3856. doi: 10.1038/s41467-024-48180-w. Nat Commun. 2024. PMID: 38719852 Free PMC article.
The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent mpox during the 2022 global outbreak. ...We find that delaying the second dose of MVA-BN vaccination will provide more durable protection and may be opti …
The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent mpox during the 2022 …
Dose-related effects of smallpox vaccine.
Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, Rothman AL, Kennedy JS, Wolff M, Belshe RB, Ennis FA. Frey SE, et al. N Engl J Med. 2002 Apr 25;346(17):1275-80. doi: 10.1056/NEJMoa013431. Epub 2002 Mar 28. N Engl J Med. 2002. PMID: 11923489 Free article. Clinical Trial.
BACKGROUND: We conducted a double-blind, randomized trial of three dilutions of vaccinia virus vaccine in previously unimmunized adults in order to assess the clinical success rates, humoral responses, and virus-specific activity of cytotoxic T cells and inte …
BACKGROUND: We conducted a double-blind, randomized trial of three dilutions of vaccinia virus vaccine in previously unimmuniz …
Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis.
Malone SM, Mitra AK, Onumah NA, Brown A, Jones LM, Tresvant D, Brown CS, Onyia AU, Iseguede FO. Malone SM, et al. Int J Environ Res Public Health. 2023 Feb 8;20(4):2963. doi: 10.3390/ijerph20042963. Int J Environ Res Public Health. 2023. PMID: 36833653 Free PMC article.
Most of the cases (56,171, 67.4%) were reported from countries in North America. Limited data on vaccine effectiveness in the current mpox outbreak are available. However, the modified vaccinia virus (smallpox vaccine) has been predicted to prevent …
Most of the cases (56,171, 67.4%) were reported from countries in North America. Limited data on vaccine effectiveness in the current …
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine.
Greenberg RN, Schmidt D, Reichhardt D, Roesch S, Vidojkovic S, Maclennan J, Chen LM, Gruenert R, Kreusel C, Weidenthaler H, Meyer TPH, Chaplin PJ. Greenberg RN, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2384189. doi: 10.1080/21645515.2024.2384189. Epub 2024 Aug 22. Hum Vaccin Immunother. 2024. PMID: 39171509 Free PMC article. Clinical Trial.
Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation in the US, Canada, and EU. ...In a phase 2 clinical trial, 651 vaccinia-naive participants were vaccinated with two doses …
Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) f …
Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.
Liu H, Wang W, Zhang Y, Wang F, Duan J, Huang T, Huang X, Zhang T. Liu H, et al. Emerg Microbes Infect. 2024 Dec;13(1):2387442. doi: 10.1080/22221751.2024.2387442. Epub 2024 Aug 16. Emerg Microbes Infect. 2024. PMID: 39082272 Free PMC article.
A large outbreak of monkeypox occurred in 2022, and most people lack immunity to orthopoxvirus. Smallpox vaccination is essential for preventing further smallpox outbreaks. This study evaluated the effectiveness, protection, safety, and cross-immunogen …
A large outbreak of monkeypox occurred in 2022, and most people lack immunity to orthopoxvirus. Smallpox vaccination is essent …
Safety and immunogenicity of IMVAMUNE smallpox vaccine using different strategies for a post event scenario.
Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB. Frey SE, et al. Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050. Epub 2013 May 9. Vaccine. 2013. PMID: 23664987 Free PMC article. Clinical Trial.
INTRODUCTION: Reintroduction of Variola major as an agent of bioterrorism remains a concern. A shortened dosing schedule of Bavarian Nordic's (BN) IMVAMUNE( ) (modified vaccinia Ankara vaccine against smallpox) was compared to the currently recommended 0- and …
INTRODUCTION: Reintroduction of Variola major as an agent of bioterrorism remains a concern. A shortened dosing schedule of Bavarian …
Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost.
Liu Y, Lv W, Shan P, Li D, Wu YQ, Wang YC, Li YY, Liu Q, Wang JS, Hao YL, Liu Y, Huang WJ, Ren L, Wang SH, Li TS, Xu J, Shao YM. Liu Y, et al. Signal Transduct Target Ther. 2025 Jul 2;10(1):208. doi: 10.1038/s41392-025-02259-y. Signal Transduct Target Ther. 2025. PMID: 40593459 Free PMC article. Clinical Trial.
Developing a safe and effective vaccine remains a global priority for ending the human immunodeficiency virus (HIV) pandemic. ...The most commonly observed AEs were redness and papule at rTV vaccination sites and axillary enlarged lymph nodes at the same rTV …
Developing a safe and effective vaccine remains a global priority for ending the human immunodeficiency virus (HIV) pandemic. …
Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.
Troy JD, Hill HR, Ewell MG, Frey SE. Troy JD, et al. Vaccine. 2015 Oct 5;33(41):5425-5431. doi: 10.1016/j.vaccine.2015.08.032. Epub 2015 Aug 28. Vaccine. 2015. PMID: 26319063 Free PMC article.
INTRODUCTION: Previous research shows immune response to vaccination differs by sex but this has not been explored for IMVAMUNE, a replication-deficient smallpox vaccine developed in response to the potential for bioterrorism using smallpox. ...Models …
INTRODUCTION: Previous research shows immune response to vaccination differs by sex but this has not been explored for IMVAMUNE, a re …
50 results